Point72 Hong Kong’s Century Therapeutics IPSC Stock Holding History

Point72 Hong Kong’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-186	Closed	-$2K	–	2155
2022 Q2	$2K	Buy	+186	New	+$1.82K	﹤0.01%	1786

Other funds holding IPSC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Point72 Hong Kong's IPSC Position: Q3 2022 in Review

Point72 Hong Kong sold out of Century Therapeutics (IPSC) in Q3 2022, closing a stake of 186 shares — an estimated $2K sold.

Point72 Hong Kong first reported a position in IPSC in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 54 funds tracked by Wall St. Rank hold IPSC as of Q3 2022.

Point72 Hong Kong reported no remaining Century Therapeutics position as of Q3 2022 after selling out during the quarter.
Point72 Hong Kong sold 186 Century Therapeutics shares in Q3 2022, an estimated $2K.
Point72 Hong Kong first reported a position in Century Therapeutics in Q2 2022 and held it in 1 quarter.
Point72 Hong Kong's Century Therapeutics position peaked at $2K in Q2 2022.
54 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.